Sepsis-associated encephalopathy (SAE), characterized as diffuse brain dysfunction and neurological manifestations secondary to sepsis, is a common complication in critically ill patients and can give rise to poor outcome, but understanding the molecular basis of this disorder remains a major challenge. Given the emerging role of G protein-coupled receptor 2 (GRK2), first identified as a G protein-coupled receptor (GPCR) regulator, in the regulation of non-G protein-coupled receptor-related molecules contributing to diverse cellular functions and pathology, including inflammation, we tested the hypothesis that GRK2 may be linked to the neuropathogenesis of SAE. When mouse MG6 microglial cells were challenged with lipopolysaccharide (LPS), GRK2 cytosolic expression was highly up-regulated. The ablation of GRK2 by small interfering RNAs (siRNAs) prevented an increase in intracellular reactive oxygen species generation in LPSstimulated MG6 cells. Furthermore, the LPS-induced upregulation of inducible nitric-oxide synthase expression and increase in nitric oxide production were negated by GRK2 inhibitor or siRNAs. However, GRK2 inhibition was without effect on overproduction of tumor necrosis factor-a, interleukin (IL)-6, and IL-1b in LPS-stimulated MG cells. In mice with cecal ligation and puncture-induced sepsis, treatment with GRK2 inhibitor reduced high levels of oxidative and nitrosative stress in the mice brains, where GRK2 expression was upregulated, alleviated neurohistological damage observed in cerebral cortex sections, and conferred a significant survival advantage to CLP mice. Altogether, these results uncover the novel role for GRK2 in regulating cellular oxidative and Abbreviations used: AP-1, activator protein-1; CLP, cecal ligation and puncture; CM-H 2 DCFDA, 5-(and-6)-chloromethyl-2'7'-dichlorofluorescein diacetate, acetyl ester; CNS, central nervous system; DHE, dihydroethidine hydrochloride; ELISA, enzyme-linked immunosorbent assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPCR, G protein-coupled receptor; GRK2, G protein-coupled receptor 2; ICU, intensive care units; IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MDA, malondialdehyde; NF-jB, nuclear factor-jB; NO, nitric oxide; NOx, nitrite and nitrate; OCT, optimum cutting temperature; PCR, polymerase chain reaction; ROS, reactive oxygen species; RRIS, Research Resource Identifier; SAE, sepsis-associated encephalopathy; siRNA, small interfering RNA; SOD, superoxide dismutase; STAT, signal transducer and activator of transcription; TNF-a, tumor necrosis factor-a.
small interfering RNAs (siRNAs) prevented an increase in intracellular reactive oxygen species generation in LPSstimulated MG6 cells. Furthermore, the LPS-induced upregulation of inducible nitric-oxide synthase expression and increase in nitric oxide production were negated by GRK2 inhibitor or siRNAs. However, GRK2 inhibition was without effect on overproduction of tumor necrosis factor-a, interleukin (IL)-6, and IL-1b in LPS-stimulated MG cells. In mice with cecal ligation and puncture-induced sepsis, treatment with GRK2 inhibitor reduced high levels of oxidative and nitrosative stress in the mice brains, where GRK2 expression was upregulated, alleviated neurohistological damage observed in cerebral cortex sections, and conferred a significant survival advantage to CLP mice. Altogether, these results uncover the novel role for GRK2 in regulating cellular oxidative and Sepsis is a common reason for admission to intensive care units (ICUs) and remains the major cause of death from microbial infection, despite recent advances in medical interventions, including antibiotics, and supportive care (Wang et al. 2007; Angus and van der Poll 2013) . Sepsis has been now redefined as a life-threatening organ dysfunction condition because of a dysregulated response of the host to infection (Singer et al. 2016) . In sepsis, thus, uncontrolled, excessive, and overwhelming systemic inflammation can lead to impaired function of vital organs, including the brain (Sweis et al. 2016; Hattori et al. 2017) . Sepsis-associated encephalopathy (SAE) represents diffuse cerebral dysfunction during sepsis when the source of infection is located outside of the central nervous system (CNS) (Gofton and Young 2012) . Its neurological symptoms vary from lethargy and delirium to coma (Sweis et al. 2016) , and, despite the most frequently observed form of encephalopathy in ICUs, the incidence of SAE also varies from 9% to 71% of septic patients, probably depending on the inclusion of criteria employed (Siami et al. 2008) . The presence of SAE is perceived to occur in parallel with extensive treatment time in ICUs and has been considered to be an independent predictor of death (Sprung et al. 1990; Iwashyna et al. 2010; Gofton and Young 2012) . Moreover, sepsis survivors have an increased risk of complicated long-term cognitive deficits and psychiatric disorders (Iwashyna et al. 2010; Gofton and Young 2012; Widmann and Heneka 2014) . Although dysregulated inflammation in the CNS is assumed to be the key cause leading to SAE, the underlying mechanisms responsible for the pathogenesis of SAE remain to be elucidated and any effective therapy against SAE is still lacking.
G protein-coupled receptor kinases (GRKs) are originally considered as the regulators of G protein-coupled receptor (GPCR) signaling through desensitization but their cellular role, in which GRKs, notably GRK2, can interact with a growing number of non-GPCR substrates involved in signaling and trafficking, has been articulated (Penela et al. 2010) . Importantly, a novel role of GRK2 in regulating cellular oxidative stress has been found in macrophages, vascular endothelial cells, and cardiomyocytes Sorriento et al. 2013; Taguchi et al. 2014; Theccanat et al. 2016) . Our previous study has shown that oxidative and nitrosative stress can contribute to the SAErelated histopathological changes in mice with cecal ligation and puncture (CLP)-induced sepsis (Yokoo et al. 2012) .
Therefore, it was of interest to address whether GRK2 participates in the pathogenesis of SAE through the regulation of oxidative and nitrosative stress.
In the present study, we found using cultured mouse microglia, the resident macrophages in the CNS (Ohashi et al. 2015 ) that GRK2 was up-regulated by challenge with lipopolysaccharide (LPS) and the knockdown of GRK2 gene expression abrogated the LPS-induced increase in the production of reactive oxygen species (ROS) and nitric oxide (NO). Furthermore, the pharmacological inhibition of GRK2 was shown to down-regulate ROS generation and inducible NO synthase (iNOS) expression and to prevent the neurohistopathological changes in brains of mice with CLPinduced sepsis, indicating GRK2 as a novel target for SAE management and treatment.
Materials and methods
This study was not pre-registered.
Cell culture
Mouse microglial cell line MG6 cells (RCB2403, RRID: CVCL_8732) were obtained from RIKEN BRC (Tsukuba, Japan). Cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 10 lg/mL insulin, 10 lM 2-mercaptoethanol, 100 U/mL penicillin, and 100 lg/mL streptomycin in a 5% CO 2 incubator at 37°C. A mixture of four small interfering RNAs (siRNAs) for GRK2 (siGENOME SMARTpool #M-040967-00, Dharmacon, Lafayette, CO, USA) was transfected at a final concentration of 20 nM using Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA, USA) according to the manufacture's protocol. Negative control siRNA (MISSION siRNA universal negative control, SIC-001) was purchased from SigmaAldrich (St. Louis, MO, USA).
Ethics and animals
All animal studies were conducted in accordance with the National Institute of Health Guidelines on the use of laboratory animal and with approval of the Animal Care and Use Committee of the University of Toyama (A2017MED-26, A2016MED-55). All efforts were made to minimize animal suffering such as, including less surgical stress (small incision and negligible bleeding) with suitable anesthesia, and by using only the number of animals necessary to produce reliable results. Post-operative analgesia was not given to the animals because of concerns about the interaction between analgesia and the pathobiology of sepsis (Marshall et al. 2005) . Male C57BL/6J mice (C57BL/6JJmsSlc) were obtained from Japan SLC (Hamamatsu, Shizuoka, Japan) and housed in a plastic mouse-cage in a specific pathogen-free and temperature-controlled (20-26°C) room under 12 : 12 light/dark cycle. The animals were fed with food and water ad libitum.
Animal model of sepsis
The surgical procedure to generate CLP-induced sepsis was performed as described elsewhere (Yokoo et al. 2012; Wang et al. 2015; Hattori et al. 2016) . Prior to surgery, mice were identified by tail coloring and were randomly split into the groups using an online tool (https://www.graphpad.com/quickcalcs/). In brief, male C57BL/6J mice, 8-12 weeks old (21-25 g), were anesthetized with 3-4% sevoflurane by inhalation. We used tail clamping to assess consciousness and determine a sufficient depth of anesthesia. After sufficient anesthesia was established, a middle abdominal incision was made. The cecum was mobilized, tightly ligated (1 cm from the cecum tip), punctured twice with a 21-gauge needle, and gently squeezed to expel small amounts of feces. Then, the bowel was repositioned to the peritoneal cavity, and the laparotomy site was closed with sterile suture. Sham-operated control underwent the same procedure except for ligation and puncture of the cecum. CLP mice were all lethargic, showed lack of interest in their environment, displayed piloerection, and had crusty exudates around their eyes, as contrasted with sham-operated mice that were healthy, moving freely, and eating (Takano et al. 2011; Yokoo et al. 2012) . No mice were omitted for the present study. Some mice were injected intravenously with the GRK2 inhibitor methyl 5-[2-(5-nitro-2-furyl) vinyl]-2-furoate (200 lg/kg; Calbiochem, San Diego, CA, USA) immediately before (10 : 00 a.m.) and 12 h (10 : 00 p.m.) after surgery (Taguchi et al. 2012) . The injection volume was 10 mL/kg in a 5% dimethylsulfoxide/95% saline. Animals were behaviorally observed and body temperature was monitored at 12 and 20 h after surgery. At 24 h after surgery, the animals were anesthetized with 100 lL of 20 mg/mL ketamine and 2 mg/mL xylazine. When there was no response to tail pinch, mice were perfused with saline containing heparin and brains were harvested.
Sample size
Post-hoc power analysis was performed according to a power analysis (PRISM, t-test comparison of the mean). Based on a twosample t-test with a specified mean difference of interleukin (IL)-6 levels between the sham and CLP group, an estimated standard deviation, and a = 0.05, power > 0.8 for a sample size of n = 5 per groups. We assigned 5-9 mice in each groups because this number was close to the prediction.
Immunofluorescence staining Cells and brain tissue sections were exposed to the fluorescent antibody Alexa Fluor 488-conjugated anti-rabbit, Fluor 546-conjugated F(ab')2 fragment of goat anti-mouse, and Fluor 546-conjugated anti-rat IgG (Invitrogen, Carlsbad, CA, USA) after overnight incubation with the primary antibody, anti-human GRK2 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA RRID:AB_630931), APC-Cyanine7 anti-human/mouse CD11b rat monoclonal antibody (Tonbo Bioscience, San Diego, CA, USA RRID:AB_2621625), anti-Iba-1 rabbit polyclonal antibody (Wako Pure Chemical, Osaka, Japan RRID:AB_839504), anti-mouse CD16/32 (2.4G2) rat monoclonal antibody (Tonbo, RRID: AB_2621487), and anti-mouse iNOS mouse monoclonal antibody (Santa Cruz Biotechnology, RRID:AB_627810), respectively. The nucleus was counter-stained with Hoechst 33342 dye (Invitrogen). Immunofluorescence images were observed under a Zeiss (Oberkochen, Germany) LSM780 Laser Scanning Microscope and processed using Adobe Photoshop CC software (Adobe, San Jose, CA, USA).
Western blot analysis
Cells were harvested and lysed in 300 lL of Radio-Immunoprecipitation Assay (RIPA) buffer (25 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, pH 7.4) (Thermo Fisher Scientific, Rockford, IL, USA) containing protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). Brain tissues were removed, rinsed in sterilized phosphatebuffered saline on ice, and homogenized. Then, the lysates and homogenates were centrifuged at 18 000 g for 10 min at 4°C, and the resulting supernatants were collected. The proteins in the supernatant were measured using BCA Protein Assay Kit (Thermo Fisher Scientific). Blotting procedure, chemiluminescent detection, and densitometric analysis were performed as described in our previous reports (Sakata et al. 2015; Wang et al. 2015; Sakai et al. 2017) . Samples (20 lg of protein) were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane. The membrane was blocked for 60 min at 24-26°C in Odyssey blocking buffer, followed by overnight incubation with primary antibody, anti-human GRK2 rabbit polyclonal antibody (1 : 500; Santa Cruz Biotechnology RRID:AB_630931), anti-mouse iNOS rabbit polyclonal antibody (1 : 1000; Cell Signaling, Danvers, MA, USA RRID:AB_1136063), or anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mouse monoclonal antibody (1 : 5000; Wako Pure Chemical, RRID: AB_2665526), at 4°C. Primary antibody detection was performed with horseradish peroxidase-conjugated secondary antibodies. Binding of the antibody was detected by an Enhanced ChemiLuminescence (ECL) Plus chemiluminescent system (GE Healthcare, Tokyo, Japan) and levels of protein expression were quantitated by a luminoimage LAS-4000 analyzer (Fuji Film, Tokyo, Japan).
RNA extraction and quantitative real-time polymerase chain reaction Total RNA was isolated from cells and brain tissues with Sepazol-RNA I Super G (Nacalai Tesque). RNA was reverse-transcribed to cDNA by the use of PrimeScript RT Master Mix (Takara Bio, Ohtsu, Japan) or ReverTra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan), and real-time polymerase chain reaction (PCR) analyses were performed using SYBR Premix Ex Taq II (Tli RNaseH Plus), ROX plus (Takara Bio). The PCR program consisted of 95°C for 30 s for initial denaturation of DNA, followed by 40 cycles of 95°C for 10 s and 60°C for 30 s for annealing of primers and elongation. Values were normalized to GAPDH according to the manufacturer's protocol (MX3000P real-time PCR system; Agilent Technologies Inc., Santa Clara, CA, USA). The PCR primers were designed as follows: forward 5'-GTTCTCAGCCCAACAATACAAGA-3' and reverse 5'-GT GGACGGGTCGATGTCAC-3' for iNOS, forward 5'-GTTCTA TGGCCCAGACCCTCAC-3 0 and reverse 5 
Measurement of ROS production
To detect intracellular ROS, cells were loaded with the fluorescent probe 5-(and-6)-chloromethyl-2'7'-dichlorofluorescein diacetate, acetyl ester (CM-H 2 DCFDA; Thermo Fisher Scientific) to a final concentration of 40 lM for 30 min at 37°C. Cells were harvested by TrypLE and then analyzed on a FACS Accuri (BD Biosciences, Franklin Lakes, NJ, USA). When we assessed levels ROS generation in the brain, brain tissues were immediately embedded in optimum cutting temperature compound. Unfixed frozen samples were cut into 10-lm thick sections and placed on glass slide. The fluorescence probe dihydroethidine hydrochloride (DHE; Thermo Fisher Scientific) at 5 lM was applied to each tissue section and then incubated in a light-protected humidified chamber at 37°C for 30 min. One investigator (MK) weas blinded to the animal's treatment groups and counted the number of DHE-positive cells in the sections.
Measurement of NOx production
To assess NOx (nitrite and nitrate) production by microglia, NOx content of the medium was measured with a NO 2 /NO 3 Assay Kit-FX (Fluorometric)~2,3-Diaminonaphthalene Kit (Dojindo, Kumamoto, Japan), according to the manufacturer's instructions. The measurements were detected using a microplate reader (Molecular Devices, Menlo Park, CA, USA).
Enzyme immunoassay for cytokines
Culture medium levels of TNF-a, IL-1b, and IL-6 were measured by the use of commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. The plate was read on a microplate reader (Molecular Devices). Assays were performed in duplicate.
Measurements of MDA and SOD
The malondialdehyde (MDA) content and superoxide dismutase (SOD) activity in brain tissues were measured by using the commercially available assay kits (JaICA, Shizuoka, Japan; Dojindo) according to the manufactures' instructions. The data were analyzed with a microplate reader (Molecular Devices).
Histological examination
The brains were fixed by immersion in 10% buffered formaldehyde overnight, embedded in paraffin, and cut into 5-lm thick coronal sections. After deparaffinization, brain sections were stained with hematoxylin and eosin for routine histological evaluation. One investigator (MK) were blinded to the animal's treatment groups, evaluated and counted cell shape and number in the histological sections by ImageJ (Nationnal Institute of Health, Bethesta, MD, USA). Cell shape and number were quantified using the measurement and analysis software ImageJ.
Survival studies
Mice were randomly divided into three groups based on an online randomization tool (https://www.graphpad.com/quickcalcs/). The first group underwent CLP alone, and the second group was continuously given GRK2 inhibitor (56.4 ng/kg/day) through an osmotic pump that was implanted into the peritoneal cavity immediately following CLP. Additional mice were subjected to sham operation. The animals were allowed free access to food and water, and the survival time of each animal was recorded for 7 days.
Statistical analysis
Data were analyzed by the use of Prism software (version 6; GraphPad Software, San Diego, CA, USA). Comparisons between two groups were analyzed by using a two-tailed Student's t-test, and comparisons between more than two groups were analyzed by a one-way ANOVA followed by Tukey's multiple comparison test. Differences at p < 0.05 were considered statistically significant. Values are presented as mean AE SD. The number of samples and animals is indicated in the corresponding figure legends.
Results

Effect of LPS on GRK2 expression in microglia
We initially investigated whether LPS challenge can make a change in GRK2 expression in the mouse microglial cell line MG6 cells. Modest levels of GRK2 were expressed by MG6 cells. When LPS (1 lg/mL) was applied to MG6 cells, the expression levels of GRK2 in the cytoplasm were increased in a time-dependent manner (Fig. 1a) . The LPS-induced upregulation of GRK2 cytoplasmic expression in MG6 cells was detected at 3 h, peaked at 6 h, and persisted up to 15 h following LPS. In addition, the translocation of GRK2 to the plasma membrane was evident at 24 h after LPS challenge. Co-immunostaining with anti-CD11b antibody, a surface microglial marker, showed that GRK2 was localized to the plasma membrane site at 24 h following LPS challenge (Fig. 1b) . When MG6 cells were treated with LPS in the dose range of 1 ng/mL-10 lg/mL for 15 h, LPS up-regulated GRK2 cytosolic expression in a dose-dependent manner (Fig. 1c) . Indeed, GRK2 were increased 2.5-fold (p < 0.05) and 4.1-fold (p < 0.01) compared with untreated cells when LPS was given at a dose of 10 ng/mL and 1 lg/mL, respectively.
Effect of GRK2 inhibition on LPS-induced inflammatory responses of microglia
The knockdown of GRK2 was conducted in MG6 cells using siRNAs. Our transfection of GRK2 siRNAs effectively silenced microglial expression of GRK2 protein (Fig. 2a) . When intracellular ROS were measured using the fluorescence dye CM-H 2 DCFDA, exposure of MG6 cells to 1 lg/ mL LPS for 12 h led to a significant increase in intracellular fluorescence (Fig. 2b) . Transfection of GRK2 siRNAs almost completely prevented the increase in ROS-induced intracellular fluorescence in LPS-stimulated cells. LPS challenge also caused a time-dependent up-regulation of iNOS mRNA in MG6 cells (Fig. 2c) . The ablation of GRK2 by siRNAs resulted in a marked inhibition of the LPSinduced increase in iNOS mRNA levels. Furthermore, the increase in iNOS protein expression in LPS-stimulated MG6 cells was significantly inhibited by GRK2 siRNA transfection (Fig. 2d) . Finally, transfection of GRK2 siRNAs blunted an increase in NOx production when MG6 cells were challenged with LPS (Fig. 2e) . The increased levels of iNOS mRNA in LPS-stimulated MG6 cells were also abrogated by treatment with 10 lM GRK2 inhibitor (Fig. 3a) . Treatment with GRK2 inhibitor also abolished the LPS-induced increases in iNOS protein and NOx production ( Fig. 3b and c) . In the presence of 10 lM GRK2 inhibitor, however, no substantial inhibition of mRNA levels for TNF-a, IL-6, and IL-1b, which were all markedly up-regulated by LPS, occurred (Fig. 4a-c) . When GRK2 inhibitor was used at a concentration of 100 lM, the up-regulation of TNF-a mRNA was unchanged and that of IL-1b mRNA was slightly but significantly inhibited in LPSstimulated cells (Fig. 4d and e) . In line with the lack of effect on GRK2 inhibitor on TNF-a, IL-6, and IL-1b mRNAs, when the amounts of these proinflammatory cytokines in culture media were measured by ELISA, LPS challenge resulted in striking increases in protein levels of TNF-a, IL-6, and IL-1b secreted by MG6 cells regardless of whether GRK2 inhibitor was present (Fig. 4f-h ).
Expression of GRK2 in brain tissues of CLP mice
Western blot analysis of GRK2 revealed that its cerebral expression was evidently higher in mice at 24 h after CLPinduced sepsis than in sham-operated controls (Fig. 5a ). Confocal immunofluorescence microscopy was conducted to visualize GRK2 in brain cells (Fig. 5b) . In the immunofluorescence staining, we found that GRK2 was apparently increased when mice were subjected to CLP. Doublelabeling immunofluorescence showed that many microglia, which were stained with anti-Iba-1 antibody, a microglial marker, were labeled with anti-GRK2 antibody (Fig. 5c) . It should be, however, noted that GRK2 were also present in other brain regions which were not identified by staining with anti-Iba1. 3 samples) , IL-6 (n = 3 samples), and IL-1b (n = 3 samples) after LPS challenge. GRK2 inhibitor at a concentration of 10 lM was given at 30 min before challenge with 100 ng/mL LPS. The mRNA levels were expressed as a fold increase above control normalized glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (d and e) Concentration-dependent effect of GRK2 inhibitor on the LPS-induced up-regulation of TNF-a and IL-1b mRNAs. GRK2 inhibitor was treated at 0-100 lM for 30 min followed by challenge with 100 ng/mL LPS for 3 h (n = 4 samples). (f-h) Cell culture media were collected at 24 h after LPS challenge, and then TNF-a, IL-6, and IL-1b were measured by ELISA (n = 3 samples). *p < 0.05 versus the respective value obtained at time 0. # p < 0.05 versus the respective value obtained LPS alone. We measured ROS production in brain tissues using the oxidative fluorescence dye DHE (Fig. 6a) . CLP-induced sepsis resulted in a significant increase in the fluorescence intensity in brain tissues. When GRK2 inhibitor was administered, the sepsis-induced increase in the fluorescence intensity was significantly inhibited. To further support the inhibitory effect of GRK2 inhibitor on ROS generation, we assessed MDA content, which is the most mutagenic product of lipid peroxidation, in brain tissues (Fig. 6b) . In CLP-induced septic mice, brain MDA content was greatly increased, which was significantly lowered by GRK2 inhibitor treatment. In contrast, the activity of the antioxidant enzyme SOD was significantly diminished in brain tissues of CLP mice and GRK2 inhibitor treatment prevented the sepsis-induced reduction in SOD activity (Fig. 6c) . Effect of GRK2 inhibitor treatment on nitro-oxidative stress in brain tissues of mice with CLP-induced sepsis. GRK2 inhibitor (200 lg/ kg) was injected intravenously immediately before and 12 h after surgery. Brain tissues were harvested from the animals at 24 h after surgery. (a) Reactive oxygen species (ROS) generation in brain tissues of mice (sham n = 7 mice, CLP n = 9 mice, sham + GRK2 inhibitor n = 5 mice, CLP + GRK2 inhibitor n = 7 mice). The oxidative fluorescence dye dihydroethidine hydrochloride (DHE) was used for measuring ROS production. In the left trace, typical images of ROS visualization using DHE are depicted. Scale bar, 100 lm. (b) malondialdehyde (MDA) content (sham n = 6 mice, CLP n = 9 mice, sham + GRK2 inhibitor n = 6 mice, CLP + GRK2 inhibitor n = 7 mice). (c) superoxide dismutase (SOD) activity (sham n = 6 mice, CLP n = 9 mice, sham + GRK2 inhibitor n = 6 mice, CLP + GRK2 inhibitor n = 7 mice). (d) iNOS mRNA level (sham n = 7 mice, CLP n = 9 mice, sham + GRK2 inhibitor n = 5 mice, CLP + GRK2 inhibitor n = 7 mice). (e) TNF-a mRNA level (sham n = 7 mice, CLP n = 9 mice, sham + GRK2 inhibitor n = 5 mice, CLP + GRK2 inhibitor n = 7 mice). The mRNA levels were expressed as a fold increase above control normalized glyceraldehyde-3-phosphate dehydrogenase (GAPDH). *p < 0.05 versus the respective sham control value. Sepsis induction by CLP sharply up-regulated expression of iNOS mRNA in brain tissues (Fig. 6d) . Treatment with GRK2 inhibitor significantly attenuated the up-regulation of iNOS mRNA expression in brain tissues after CLP. However, GRK2 inhibitor administration was without effect on high levels of TNF-a mRNA seen in brain tissues of CLP mice (Fig. 6e) . The immunofluorescence staining for iNOS protein in brain tissue sections also revealed that the increase in its cerebral expression in CLP mice was prevented by treatment with GRK2 inhibitor (Fig. 6f) . In the immunofluorescence images, the regions that reacted positively following staining for iNOS included cerebral blood vessels.
Effect of GRK2 inhibitor on septic histopathological changes of brains As demonstrated in our previous report (Yokoo et al. 2012) , histopathological analysis of the sections stained with hematoxylin and eosin showed significant changes in the morphology of neurons in the cerebral cortex following CLP-induced sepsis ( Fig. 7a and b) . Thus, they were largely characterized by hypereosinophilic and shrunken cytoplasm with deeply stained and irregularly shaped nuclei. Such histopathological changes were dissipated by treatment with GRK2 inhibitor.
CD16/32 is a marker for activated microglia as a proinflammatory phenotype. The brain tissues from CLP mice displayed an increase in microglia, which were recognized by Iba-1 (Fig. 7c) . This microglia were also labeled with CD16/32. When CLP mice were treated with GRK2 inhibitor, CD16/32-positive microglia were sharply reduced.
Effect of GRK2 inhibitor on animal survival after CLP Finally, we examined whether application of GRK2 inhibitor improves survival of mice with CLP-induced polymicrobial sepsis (Fig. 8) . More than 90% of the animals subjected to CLP surgery died throughout the 3 days of observation. The animals, when continuously given GRK2 inhibitor immediately after CLP, displayed a significant survival benefit (p < 0.05, log rank test).
Discussion
GRK2 is a ubiquitously expressed member of the GRK family that was originally identified for its role in the phosphorylation and desensitization of GPCRs together with arrestins (Premont and Gainetdinov 2007; Penela et al. 2010) . In the last decade, abundant evidence has provided for new functions of GRK2 to regulate other pathways independently of its GPCR phosphorylation ability (Penela et al. 2010) . The expression levels of GRK2 have been documented to be down-regulated in immune cells from human patients with some inflammatory disorders (Lombardi et al. 1999 (Lombardi et al. , 2001 Giorelli et al. 2004; Vroon et al. 2005) . In contrast, high expression of GRK2 has been detected in neutrophils from septic patients (Arraes et al. 2006) . In this context, Toll-like receptor ligands have been reported to increase GRK2 levels in macrophages and neutrophils (Loniewski et al. 2008; Alves-Filho et al. 2009 ). In line with those reports, we showed that GRK2 cytosolic expression was highly up-regulated in LPS-stimulated microglia. Moreover, we found that the LPS-induced increases in ROS generation, iNOS expression, and NOx production were strikingly inhibited by siRNA-mediated knockdown of GRK2. We thus uncovered the novel role for GRK2 in regulating cellular oxidative and nitrosative stress in microglia following LPS challenge.
Our in vivo studies demonstrated that CLP-induced sepsis led to significant increases in ROS production and MDA content, an oxidative stress marker, in mouse brain tissues, both of which were prevented by treatment with GRK2 inhibitor. In physiological and pathological conditions, mitochondria are an important cellular source of ROS, which are generated primarily through electron leakage from the electron transport chain (Lambert and Brand 2009) . Furthermore, NADPH oxidase can also serve as a key producer of superoxide anion, a type of the principal ROS made by cells. Experimental evidence has been provided for involvement of NADPH oxidase in interferon-c-induced ROS production in microglial cells (Chuang et al. 2013) . Our previous study demonstrated a greater level of NADPH oxidase activity in brain tissues of CLP-induced septic mice than in sham-operated controls (Yokoo et al. 2012) . This observation was associated with the up-regulation of expression of the NADPH oxidase cytosolic components, p47 phox and p67
phox (Yokoo et al. 2012) . Therefore, there may be a transcriptional link between GRK2 and these NADPH oxidase components. In the present study, we also found that GRK2 inhibitor treatment reversed a decline in activity of the antioxidant SOD in CLP mouse brains, potentially suggesting another deleterious oxidative mechanism caused by increased GRK2 in brain tissues after sepsis.
The up-regulation of iNOS expression in the brain has been documented in animal models of sepsis (Wong et al. 1996; Yokoo et al. 2012; Wahab et al. 2016) and in septic patients (Sharshar et al. 2003) . Within the CNS, microglia and astrocytes can generate NO radicals from iNOS activation (Marcus et al. 2003; Candolfi et al. 2004) . Indeed, our in vitro experiments showed that iNOS expression was up-regulated and NO production was increased in LPS-stimulated mouse MG6 microglial cells. Besides, the iNOS protein expression in cerebral vessels was detected by its immunofluorescence staining in brain tissue sections from mice with CLP-induced sepsis, implying the induction of endothelial iNOS expression in the cerebral vessel wall after sepsis. NO produced in large quantities by iNOS is thought to be a damaging radical, which would be responsible for oxidative/nitrosative brain injury together with ROS (Pannu and Singh 2006; Garry et al. 2015) . In this study, we showed that the up-regulation of iNOS mRNA expression in LPS-stimulated MG6 cells was negated by transfection of GRK2 siRNAs or treatment with GRK2 inhibitor. Furthermore, GRK2 inhibitor treatment strongly reduced the increase in iNOS mRNA levels in mouse brain tissues after CLP. These findings suggest that GRK2 has an important role in iNOS gene transcription under inflammatory pathologic conditions. Expression of iNOS is transcriptionally regulated by a number of transcriptional factors, such as nuclear factor-jB (NF-jB), activator protein-1 (AP-1), and signal transducer and activator of transcription-1 (STAT 1), that bind to the promoter region of the iNOS gene (Xie et al. 1994; Ganster et al. 2001; Pance et al. 2002; Pautz et al. 2010) . Especially, NF-jB acts as a critical activator in expression of iNOS, and many of the proinflammatory genes, including TNF-a and IL-6, are regulated by jB sites in the DNA and have putative binding sites for NF-jB at their promoter sites to activate gene expression (Libermann and Baltimore 1990; Trede et al. 1995) . However, we found that treatment with GRK2 inhibitor at the concentration which was effective in the iNOS up-regulation was without effect on the up-regulation of gene expression of TNF-a, IL-6, and IL-1b, suggesting that GRK2 does not appear to modulate the NF-jB-mediated gene transcription. The present experiments do not allow further assumption as to the exact mechanistic link between GRK2 and iNOS gene transcription, but our study showing the iNOS expressionpromoting role of GRK2 is in good agreement with the concept that accumulating GRK2 is deleterious for the cells (Penela et al. 2010) .
As previously reported in detail (Yokoo et al. 2012) , histopathological analysis revealed serious neuronal degeneration in brains of mice with CLP-induced sepsis, as indicated by the altered morphology of cerebral cortex neurons having hypereosinophilic and shrunken cytoplasm with deeply stained and irregularly shaped nuclei. These neurohistopathological changes are likely to be associated with oxidative and nitrosative stress under the sepsis pathology. Our previous report has shown that treatment with edaravone, a free radical scavenger, can prevent such neurohistopathological changes in CLP mice (Yokoo et al. 2012) . In the present study, we found that treatment with GRK2 inhibitor prevented histopathological outcomes after CLP-induced sepsis in mice. In view of the regulatory role of GRK2 in ROS and iNOSmediated NO, it is reasonable to conclude that the beneficial effect of GRK2 inhibitor on the neurohistopathological changes in CLP mouse brains stemmed from its protection from oxidative and nitrosative stress. Besides, the lack of effect of GRK2 inhibitor on the LPS-induced up-regulation of TNF-a, IL-1b, and IL-6, these inflammatory cytokines may not be substantially responsible for sepsis-associated neurohistopathological changes in CLP mouse brains.
Microglial cells are the resident macrophages of the CNS and are implicated in immune defense and synaptic plasticity, but, upon CNS injury, transform into active phagocytic microglia, migrate to the lesion area, secrete proinflammatory cytokines, and damage neurons (Fu et al. 2014; Ohashi et al. 2015) . Microglial cells have been described to play a key role in the neuropathogenesis of SAE (Deng et al. 2013) . Microglial activation in SAE has been documented by an autopsy study showing a significant increase in expression of CD68, a microglia/macrophage marker, in brain tissues from patients who died with sepsis (Lemstra et al. 2007 ). Furthermore, minocycline, an inhibitor of microglial activation, can improve the long-term cognitive behavior of CLP mice, an effect which is associated with reduced oxidative stress and inflammatory burden in the hippocampus (Michels et al. 2014) . Our present study showed that GRK2 inhibition strikingly reduced ROS generation and iNOS-mediated NO production in LPS-stimulated microglial cells where GRK2 cytosolic expression was up-regulated, which may potentially be a pivotal mechanism involved in the protective effect of GRK2 inhibitor on the sepsis-related neurohistological damage in CLP mice. In this regard, the modulation of microglial activity, although the benefit of GRK2 inhibition could not be limited to calming microglial activation, may be an interesting option for treating SAE.
From an outcome perspective, we found that continued administration of GRK2 inhibitor conferred a significant survival advantage to CLP mice. The salutary effect of GRK2 inhibitor on the sepsis-related neurohistological damage may contribute to a reduction in septic mortality. However, the possibility cannot be ruled out that systemic application of GRK2 inhibitor may have brought a beneficial effect on peripheral organ injury in sepsis. The present experiments do not allow further speculation as to the precise mechanism(s) underlying the survival benefit of GRK2 inhibitor in mice with CLP-induced sepsis. Moreover, one may argue that administration of GRK2 inhibitor through an osmotic pump that was implanted into the peritoneal cavity immediately following CLP does not accurately represent the clinical situation. The investigation of treatment after sepsis induction would have the additional clinical value.
In conclusion, we demonstrated for the first time that GRK2, whose cytosolic expression is highly up-regulated, is a critical regulator for cellular oxidative and nitrosative stress in LPS-stimulated microglia. Whether GRK2 is able to regulate molecular events responsible for cellular oxidative and nitrosative stress by kinase-dependent or -independent mechanisms needs to be addressed in further study, but our present results provide mechanistic evidence for the deleterious effect of increased GRK2 activity in the brain. Given the potentially vital role of oxidative and nitrosative stress as a major step in the development of SAE, GRK2 may serve as an intriguing therapeutic target for the prevention or treatment of SAE. * Fig. 8 Kaplan-Meier survival curves. No deaths occurred in mice that underwent sham procedure (n = 12 mice). In the GRK2 inhibitortreated group, GRK2 inhibitor (56.4 ng/kg/day) was continuously given through an osmotic pump that was implanted into the peritoneal cavity immediately following CLP. Fifteen and 12 animals were used for untreated and GRK2 inhibitor-treated CLP groups, respectively. Mortality was observed over 7 days. *p < 0.05.
